- Report
- October 2022
- 177 Pages
From €3113EUR$3,450USD£2,705GBP
- Report
- October 2022
- 174 Pages
North America
From €3113EUR$3,450USD£2,705GBP
- Report
- October 2022
- 181 Pages
Africa, Middle East
From €3113EUR$3,450USD£2,705GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3113EUR$3,450USD£2,705GBP
- Report
- October 2020
- 133 Pages
Global
From €13532EUR$14,995USD£11,757GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2617EUR$2,900USD£2,274GBP
- Report
- March 2025
- 260 Pages
Africa
From €2617EUR$2,900USD£2,274GBP
- Report
- March 2025
- 210 Pages
Latin America
From €2617EUR$2,900USD£2,274GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €2617EUR$2,900USD£2,274GBP
- Report
- March 2025
- 980 Pages
Europe
From €2617EUR$2,900USD£2,274GBP
- Report
- March 2025
- 1400 Pages
Global
From €4422EUR$4,900USD£3,842GBP
- Report
- March 2025
- 50 Pages
Kenya
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Egypt
From €541EUR$600USD£470GBP
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Greece
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Finland
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Denmark
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Norway
From €541EUR$600USD£470GBP
- Report
- March 2025
- 50 Pages
Austria
From €541EUR$600USD£470GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more